Phaseline

Companies › Melius Pharma

Melius Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ME-015 (Suplatast Tosilate)
T-cell activation and chemokine-mediated immune response modulator
–Phase 2Idiopathic Pulmonary Fibrosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05983471ME-015 (Suplatast Tosilate)Phase 2Idiopathic Pulmonary FibrosisRespiratoryAug 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Jianmin Pharmaceutical Group Endeavor Biomedicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.